Synapse - Leora Boussi

Results (13)

Forecasting optimal treatments in relapsed/refractory mature T- and NK-cell lymphomas: A global PETAL Consortium study

Journal Article

Sorial, M. N.; Han, J. X.; Koh, M. J.; Boussi, L.; Li, S.; Duan, R.; Lu, J.; Lei, M. M.; MacVicar, C. T.; Freydman, J.; more...
British Journal of Haematology (2025)

Fulltext@MSK | Save

Barriers to chimeric antigen receptor T-cell therapy

Research Letter

Valtis, Y. K.; Chin, K. K.; Nemirovsky, D.; Devlin, S. M.; Yisraeli Salman, M.; Boussi, L.; Cadzin, B.; McLoughlin, C.; Cathcart, E.; Davis, P.; more...
JAMA Oncology (2025)

Fulltext@MSK | Save

Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: Results from the PETAL consortium

Journal Article

Han, J. X.; Koh, M. J.; Boussi, L.; Sorial, M.; McCabe, S. M.; Peng, L.; Singh, S.; Eche-Ugwu, I. J.; Gabler, J.; Fernandez Turizo, M. J.; more...
Blood Advances (2025)

Fulltext@MSK | Save

Adult AML patients with NUP98 fusions are frequently therapy-related, and are associated with monocytic differentiation, recurring mutations in NRAS, DNMT3A and WTI and poor outcome

Meeting Abstract

Yao, J.; Aypar, U.; Sethi, S.; Boussi, L.; Londono, D.; Sukhadia, P.; Berman, E.; Stein, E. M.; Dogan, A.; Xiao, W.; more...
Blood (2024)

Fulltext@MSK | Save

Venetoclax-based therapy versus intensive chemotherapy followed by allogeneic-stem cell transplantation for high-risk elderly acute myeloid leukemia

Meeting Abstract

Iat, A.; Bewersdorf, J. P.; Gilhodes, J.; Liu, Y.; Shallis, R. M.; Boussi, L.; Zucenka, A.; Bystrom, R. P.; Deangelo, D. J.; Berton, G.; more...
Blood (2024)

Fulltext@MSK | Save

The prognostic and predictive value of RUNX1 mutations in newly diagnosed acute myeloid leukemia - An international multicenter cohort study

Meeting Abstract

Bystrom, R. P.; Bewersdorf, J. P.; Liu, Y.; Schaefer, E. J.; Shallis, R. M.; Boussi, L.; Zucenka, A.; Garciaz, S.; Aguirre, L. E.; DeAngelo, D. J.; more...
Blood (2024)

Fulltext@MSK | Save

Outcomes with HMA plus venetoclax vs intensive chemotherapy in AML patients with chromosome 5 and 7 abnormalities

Meeting Abstract

Boussi, L.; Bewersdorf, J. P.; Liu, Y.; Shallis, R. M.; Aguirre, L. E.; Zucenka, A.; Garciaz, S.; Bystrom, R. P.; DeAngelo, D. J.; Stone, R. M.; more...
Blood (2024)

Fulltext@MSK | Save

Comparative analysis of outcomes with HMA plus venetoclax vs intensive chemotherapy in AML patients harboring very-high risk cytogenetics

Meeting Abstract

Aguirre, L. E.; Bewersdorf, J. P.; Liu, Y.; Shallis, R. M.; Boussi, L.; Zucenka, A.; Garciaz, S.; Bystrom, R. P.; Deangelo, D. J.; Stone, R. M.; more...
Blood (2024)

Fulltext@MSK | Save

Patients with AML and an IDH2-R172 mutation exhibit a unique response to intensive induction chemotherapy, suggesting futility of mid-cycle bone marrow biopsy and caution when considering re-induction